WASHINGTON, April 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after market close, with a conference call to follow at 5 p.m. ET.
Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolenthealth.com.
Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to the call.
An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call.
Upcoming Investor Events
Additionally, the company announced that its executive management team will participate in upcoming investor conferences.
A live audio-only webcast and replay for these events will be available, if applicable, on the investor relations section of Evolent's website, unless otherwise noted below.
About Evolent
Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in healthcare nationally. Learn more about how Evolent is changing the way healthcare is delivered by visiting www.evolent.com.
Contacts:
Seth R. Frank
Vice President, Investor Relations
Evolent
This email address is being protected from spambots. You need JavaScript enabled to view it.
571-895-3919 (W)
Last Trade: | US$11.34 |
Daily Change: | 0.07 0.62 |
Daily Volume: | 865,942 |
Market Cap: | US$1.300B |
November 07, 2024 November 07, 2024 August 08, 2024 June 04, 2024 May 09, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB